MCID: LYM118
MIFTS: 65

Lymphoma

Categories: Blood diseases, Cancer diseases, Eye diseases, Immune diseases, Neuronal diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Lymphoma

MalaCards integrated aliases for Lymphoma:

Name: Lymphoma 11 58 75 28 53 5 41 43 14 16 71
Non-Hodgkin Malignant Lymphoma Nos 33
Nhl - [non-Hodgkin Lymphoma] 33
Non-Hodgkin Lymphoma, Nos 33
Non-Hodgkin Lymphoma 33
Lymphoid Neoplasm 71
Lymphoid Cancers 71
Lymphoid Cancer 11
Lymphoma Nos 33
Lymphomas 14

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

Disease Ontology 11 DOID:0060058
MeSH 43 D008223
NCIt 49 C3208 C7065
SNOMED-CT 68 118600007 414628006
ICD10 31 C85.9
MESH via Orphanet 44 D008223
UMLS via Orphanet 72 C0024299
Orphanet 58 ORPHA223735
ICD11 33 474972159
UMLS 71 C0024299 C0598798 C0746336

Summaries for Lymphoma

MedlinePlus: 41 Lymphoma is a cancer of a part of the immune system called the lymph system. There are many types of lymphoma. One type is Hodgkin disease. The rest are called non-Hodgkin lymphomas. Non-Hodgkin lymphomas begin when a type of white blood cell, called a T cell or B cell, becomes abnormal. The cell divides again and again, making more and more abnormal cells. These abnormal cells can spread to almost any other part of the body. Most of the time, doctors don't know why a person gets non-Hodgkin lymphoma. You are at increased risk if you have a weakened immune system or have certain types of infections. Non-Hodgkin lymphoma can cause many symptoms, such as : Swollen, painless lymph nodes in the neck, armpits or groin Unexplained weight loss Fever Soaking night sweats Coughing, trouble breathing or chest pain Weakness and tiredness that don't go away Pain, swelling or a feeling of fullness in the abdomen Your doctor will diagnose lymphoma with a physical exam, blood tests, a chest x-ray, and a biopsy. Treatments include chemotherapy, radiation therapy, targeted therapy, biological therapy, or therapy to remove proteins from the blood. Targeted therapy uses drugs or other substances that attack specific cancer cells with less harm to normal cells. Biologic therapy boosts your body's own ability to fight cancer. If you don't have symptoms, you may not need treatment right away. This is called watchful waiting. NIH: National Cancer Institute

MalaCards based summary: Lymphoma, also known as non-hodgkin malignant lymphoma nos, is related to lymphoma, hodgkin, classic and lymphoma, non-hodgkin, familial. An important gene associated with Lymphoma is PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11), and among its related pathways/superpathways are IL-9 Signaling Pathways and NF-kappaB Signaling. The drugs Ferrous succinate and Nicotine have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone marrow and myeloid, and related phenotypes are immune system and hematopoietic system

Disease Ontology: 11 A hematologic cancer that affects lymphocytes that reside in the lymphatic system and in blood-forming organs.

Wikipedia: 75 Lymphoma is a group of blood and lymph tumors that develop from lymphocytes (a type of white blood... more...

Related Diseases for Lymphoma

Diseases in the Lymphoma family:

Adult Lymphoma Eye Lymphoma

Diseases related to Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 3482)
# Related Disease Score Top Affiliating Genes
1 lymphoma, hodgkin, classic 34.0 PVT1 BCL6 BCL3 BCL2 ALK
2 lymphoma, non-hodgkin, familial 33.9 TCL1A NPM1 MYC MALT1 EZH2 CXCR5
3 follicular lymphoma 33.8 TCL1A MYC EZH2 CXCR5 CCND1 BCL6
4 lymphoma, mucosa-associated lymphoid type 33.8 MYC MALT1 CXCR5 CCND1 BCL6 BCL2
5 diffuse large b-cell lymphoma 33.7 MYC EZH2 BCL6 BCL2
6 burkitt lymphoma 33.7 TCL1A PVT1 PMS2 MYC CXCR5 BCL7A
7 anaplastic large cell lymphoma 33.6 NPM1 BCL3 BCL2 ALK
8 b-cell lymphoma 33.5 TCL1A PVT1 NPM1 MYC MALT1 GAS5
9 marginal zone b-cell lymphoma 33.5 MYC MALT1 CCND1 BCL6 BCL2 BCL10
10 peripheral t-cell lymphoma 33.4 TCL1A BCL6 BCL3 BCL2 ALK
11 lymphoma aids related 33.4 TCL1A MYC BCL6
12 mantle cell lymphoma 33.4 TCL1A MYC MALT1 GAS5 EZH2 CCND1
13 gastric lymphoma 33.3 MALT1 BCL6 BCL2 BCL10
14 angioimmunoblastic t-cell lymphoma 33.3 CXCR5 BCL6 ALK
15 sezary's disease 33.2 MYC BCL6 BCL2 BCL10 ALK
16 reticulosarcoma 33.2 NPM1 MYC BCL6 BCL2 ALK
17 splenic marginal zone lymphoma 33.2 MALT1 CCND1 BCL6
18 central nervous system lymphoma 33.2 MYC BCL6 BCL2
19 mature t-cell and nk-cell lymphoma 33.1 MYC BCL6 BCL2 ALK
20 primary mediastinal b-cell lymphoma 33.1 MYC BCL6 BCL2
21 high-grade b-cell lymphoma double-hit/triple-hit 33.1 MYC EZH2 BCL6 BCL2
22 lymphoplasmacytic lymphoma 33.1 CCND1 BCL6 BCL2
23 intravascular large b-cell lymphoma 33.1 BCL6 BCL2
24 bone lymphoma 33.0 BCL6 BCL2 ALK
25 nodal marginal zone lymphoma 33.0 MALT1 BCL6 BCL2 BCL10
26 composite lymphoma 33.0 BCL6 BCL2
27 breast lymphoma 32.9 BCL6 BCL2 ALK
28 chronic lymphocytic leukemia/small lymphocytic lymphoma 32.8 CCND1 BCL6 BCL2
29 lymphoproliferative syndrome, x-linked, 1 32.8 PTPN11 NPM1 ALK
30 leukemia, acute lymphoblastic 32.8 TCL1A PTPN11 MYC CXCR5 BCL6 BCL2
31 b-cell non-hodgkin lymphoma 32.8 BCL7A BCL6
32 relapsed/refractory diffuse large b-cell lymphoma 32.8 MYC BCL6 BCL2
33 childhood lymphoma 32.8 NPM1 MYC BCL6 BCL2 ALK
34 gastrointestinal lymphoma 32.8 MALT1 CCND1 BCL6 BCL2 BCL10
35 lymphosarcoma 32.7 BCL6 BCL2
36 lung lymphoma 32.7 MALT1 BCL6
37 t-cell acute lymphoblastic leukemia 32.7 TCL6 TCL1A MYC GAS5 BCL2 BCL10
38 colon lymphoma 32.7 CCND1 BCL6 BCL2
39 adult lymphoma 32.7 NPM1 MYC BCL6 BCL2 ALK
40 paranasal sinus lymphoma 32.7 MYC BCL6 BCL2
41 diffuse large b-cell lymphoma activated b-cell type 32.7 MYC BCL6 BCL2
42 appendix lymphoma 32.6 MYC CCND1 BCL6 BCL2
43 orbit lymphoma 32.6 MALT1 BCL10
44 testicular lymphoma 32.6 BCL6 BCL2
45 heart lymphoma 32.6 BCL6 BCL2 ALK
46 leukemia, chronic lymphocytic 32.6 TCL1A PTPN11 NPM1 MYC EZH2 DLEU2
47 ureteral lymphoma 32.6 CCND1 BCL6 BCL2
48 richter's syndrome 32.6 TCL1A MYC BCL6 BCL2
49 gallbladder lymphoma 32.6 MALT1 BCL6
50 eye lymphoma 32.6 CXCR5 BCL6

Graphical network of the top 20 diseases related to Lymphoma:



Diseases related to Lymphoma

Symptoms & Phenotypes for Lymphoma

MGI Mouse Phenotypes related to Lymphoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 10.03 BCL10 BCL2 BCL3 BCL6 CCND1 CXCR5
2 hematopoietic system MP:0005397 9.93 BCL10 BCL2 BCL3 BCL6 CCND1 CXCR5
3 neoplasm MP:0002006 9.92 ALK BCL2 CCND1 EZH2 MYC NPM1
4 mortality/aging MP:0010768 9.8 ALK BCL10 BCL2 BCL3 BCL6 BCL7A
5 integument MP:0010771 9.28 ALK BCL2 BCL6 CCND1 EZH2 MALT1

Drugs & Therapeutics for Lymphoma

Drugs for Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 892)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ferrous succinate Approved Phase 4 10030-90-7
2
Nicotine Approved Phase 4 54-11-5 942 89594
3
Posaconazole Approved, Investigational, Vet_approved Phase 4 171228-49-2 147912
4
Rasburicase Approved, Investigational Phase 4 134774-45-1
5
Cladribine Approved, Investigational Phase 4 4291-63-8 20279
6
Infliximab Approved Phase 4 170277-31-3
7
Golimumab Approved Phase 4 476181-74-5
8
Teniposide Approved Phase 4 29767-20-2 34698 452548
9
Amifostine Approved, Investigational Phase 4 20537-88-6 2141
10
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
11
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
12
Palonosetron Approved, Investigational Phase 4 119904-90-4, 135729-56-5 148211 6337614
13
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
14
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
15
Ketamine Approved, Vet_approved Phase 4 6740-88-1, 1867-66-9 3821
16
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
17
Micafungin Approved, Investigational Phase 4 235114-32-6 477468
18
Treosulfan Approved, Investigational Phase 4 299-75-2 9296
19
Idarubicin Approved Phase 4 58957-92-9 42890
20
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
21
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
22
Prilocaine Approved Phase 4 721-50-6 4906
23
Simvastatin Approved Phase 4 79902-63-9 54454
24
Dimethyl sulfoxide Approved, Vet_approved Phase 4 67-68-5 679
25
Methoxsalen Approved Phase 4 298-81-7 4114
26
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
27
Zidovudine Approved Phase 4 30516-87-1 35370
28
Ribavirin Approved Phase 4 36791-04-5 37542
29
Peginterferon alfa-2b Approved Phase 4 215647-85-1, 99210-65-8
30
Ledipasvir Approved Phase 4 1256388-51-8 67505836
31
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
32
Acetylcysteine Approved, Investigational Phase 4 616-91-1 581 12035
33
Cholecalciferol Approved, Nutraceutical, Vet_approved Phase 4 67-97-0, 1406-16-2 5280795 10883523
34
Calcifediol Approved, Nutraceutical Phase 4 19356-17-3 5283731
35
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
36
Rivoceranib Investigational Phase 4 811803-05-1 11315474
37
Dexchlorpheniramine Experimental, Investigational Phase 4 25523-97-1 33036
38
Fotemustine Investigational Phase 4 92118-27-9 104799
39
Ethylene Phase 4 74-85-1 6325
40 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
41 Calciferol Phase 4
42 Cyclooxygenase Inhibitors Phase 4
43 Endothelial Growth Factors Phase 4
44 Antiprotozoal Agents Phase 4
45 Antiparasitic Agents Phase 4
46 Cytochrome P-450 Enzyme Inhibitors Phase 4
47 Tumor Necrosis Factor Inhibitors Phase 4
48 Dopamine Agents Phase 4
49 Neurokinin-1 Receptor Antagonists Phase 4
50 Serotonin 5-HT3 Receptor Antagonists Phase 4

Interventional clinical trials:

(show top 50) (show all 7982)
# Name Status NCT ID Phase Drugs
1 An Open-label,Multicenter Randomised Study of CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for the New Diagnosed Young Patients With T Cell Non-hodgkin Lymphoma Unknown status NCT01746992 Phase 4 Cyclophosphamide 750mg/m2;Vincristine 1.4mg/m2;Doxorubicin 50mg/m2;prednisone 60mg/m2;ifosfamide 2000mg/m2;pirarubicin 50mg/m2;pirarubicin 25mg/m2;Etoposide phosphate 100mg/m2;methotrexate 1500mg/m2
2 A Randomized, Controlled Mutiple-center Clinical Research on the Treatment With Yangzhengxiaoji Capsule Combination Chemotherapy for III/IV Diffuse Large B Cell Lymphoma Unknown status NCT01949818 Phase 4 Yangzhengxiaoji capsule combined with CHOP regimen;CHOP regimen
3 Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults Unknown status NCT00797810 Phase 4 Rituximab
4 Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone (PIGLETS Regimen) as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas (PTCLs) Unknown status NCT03071822 Phase 4 cisplatin;ifosfamide;gemcitabine;L-asparaginase;etoposide;dexamethasone
5 A Multicenter Study to Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's Lymphoma Patients With Isolated Anti-HBc-positivity Who Will be Treated With Rituximab Based Chemotherapy Unknown status NCT02585947 Phase 4 Tenofovir
6 Single-arm, Multi-center Clinical Study of PD-1 Antibody, Chidamide, Lenalidomide and Gemcitabine for Peripheral T-cell Lymphoma Unknown status NCT04040491 Phase 4 PD-1 blocking antibody, chidamide, lenalidomide and gemcitabine
7 Single-arm, Multi-center Clinical Study of PD-1 Antibody, Chidamide, Lenalidomide and Etoposide for Relapsed or Refractory Natural Killer/T Cell Lymphoma Unknown status NCT04038411 Phase 4 PD-1 Antibody, chidamide, lenalidomide and etoposide
8 A Clinical Trial of Decitabine Combined With CODOX-M/IVAC in Relapsed or Refractory T-lymphoblastic Lymphoma Unknown status NCT03558412 Phase 4 Decitabine
9 A Randomized Controlled Clinical Trial of Apatinib Combined With CHOP Regimen in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma Unknown status NCT03631862 Phase 4 Apatinib;CHOP Regimen
10 Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma Unknown status NCT03513601 Phase 4 (R)-CHOP regimen;(R)-CVP regimen
11 A Multi-Center, Open-Labelled, Pralatrexate Study in Asian Patients With Peripheral T-cell Lymphoma After Prior Therapy Unknown status NCT03150602 Phase 4 Pralatrexate
12 A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma Unknown status NCT03579082 Phase 4 Decitabine
13 A Clinical Trial of Chidamide Combined With Etoposide in Relapsed or Refractory NK/T-cell Lymphoma Unknown status NCT04490590 Phase 4 Chidamide+ Etoposide
14 A Randomized Controlled Multi-center Clinical Trial on Treatment of Stage I/II NK/T Cell Lymphoma With DDGP Regiment (Gemcitabine,Pegaspargase,Cisplatin,Dexamethasone) Unknown status NCT01501136 Phase 4
15 A Randomized Controlled Multi-center Clinical Trial on Treatment of Stage Ⅲ/Ⅳ NK/T Cell Lymphoma With DDGP Regiment (Gemcitabine,Pegaspargase,Cisplatin,Dexamethasone) Unknown status NCT01501149 Phase 4 DDGP(cisplatin,dexamethasone,gemcitabine,pegaspargase);Modified SMILE (MTX,DEX,IFO,L-ASP,Etoposide,Mesna)
16 Single-arm, Multi-center Clinical Study of Crizotinib Combined With Etoposide Capsule Followed by Auto-HSCT for Relapsed and Refractory Anaplastic Lymphoma Kinase (ALK)-Positive Anaplastic Large Cell Lymphoma (ALCL) Unknown status NCT03707847 Phase 4 Crizotinib;Etoposide Capsule
17 Lenalidomide, Rituximab and Combination Chemotherapy Versus Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Highly Aggressive Non-Hodgkin B-cell Lymphoma Unknown status NCT04152577 Phase 4 R2-combination chemotherapy;R-combination chemotherapy
18 Cost-Effectiveness Study of Pegylated Recombinant Human Granulocyte Colony-stimulating Factor(PEG-rhG-CSF) in Prophylactic Treatment of Neutropenia After Chemotherapy in Lymphoma Unknown status NCT04083079 Phase 4 PEG-rhG-CSF;rhG-CSF
19 PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia Unknown status NCT02996617 Phase 4 rhG-CSF regimen;Pegylated rhG-CSF regimen
20 Study of PD-1 Monoclonal Antibody in Combination With Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Unknown status NCT04134247 Phase 4 PD-1 combined with chemotherapy;chemotherapy
21 Anti-CD19:TCRζ Chimeric Antigen Receptor-T Cells in the Treatment for Chemotherapy-resistant or Refractory CD19+B Cell Lymphoma:a Double-arm, Single Center, Open-label Clinical Trial Unknown status NCT02992834 Phase 4
22 Clinical Application of Polyethylene Glycol Liposome Doxorubicin (PLD) in Primary Lymphoma Unknown status NCT02526823 Phase 4 R-CHOP/CHOPE or ABVD chemotherapy regimen;R-CDOP/CDOPE or DBVD chemotherapy regimen
23 Hematology , Shanghai Jiaotong University Affiliated Shanghai First People's Hospital, Shanghai, China Unknown status NCT02938741 Phase 4 Anti-human Thymoglobulin;Placebo
24 EDOCH Alternating With DHAP Regimen Combined Rituximab or Not to Treat New Diagnosed Younger (Age≤65 Years) Mantle Cell Lymphoma in China: A Multicentre Phase III Trial Unknown status NCT02858804 Phase 4 Etoposide;Doxorubicin;Dexamethasone;Vincristine;Cyclophosphamide;Cytarabine;Cisplatin;Rituximab;Thalidomide;Prednisone
25 The Prospective Study of FVD Program and HD-MTX-Ara-C Program Contrast in the Treatment of PCNSL Lymphoma. Unknown status NCT01960192 Phase 4 HD-MTX-Ara-C regimen;FVD regimen
26 Efficacy and Safety of Erythropoietin in the Treatment of Anemia in Patients With Lymphoma After Autologous Hematopoietic Stem Cell Transplantation Unknown status NCT03010579 Phase 4 erythropoietin;iron supplementation
27 Optimization of the Primary Therapy for Patients With Hodgkin's Lymphoma and Evaluation of the Positron Emission Tomography (PET) as a Diagnostic Tool for Primary Staging and Assessment of the Effects of the Therapy Unknown status NCT00188149 Phase 4 Combined chemotherapy (ABVD, BACOPP-D)
28 Prophylactic Use of Entecavir for HBsAg Negative/HBcAb Positive/Hepatitis B Virus DNA Negative Patients With Lymphoma Unknown status NCT01765231 Phase 4 Entecavir prophylaxis;Observation arm
29 A Single Center Randomized Controlled Trial of the Efficacy and Safety of PEG-rhG-CSF After Autologous Hematopoietic Stem Cell Transplantation for Lymphoma Patients Unknown status NCT02905942 Phase 4 PEG-rhG-CSF;rhG-CSF
30 Prophylactic Use of Entecavir for HBsAg Positive Lymphoma Patients Treated With Rituximab-based Immunochemotherapy Unknown status NCT01768195 Phase 4 Entecavir prophylaxis
31 Self-control Trial to Evaluate the Role of Aprepitant in the Prophylaxis of Post-lumbar-punture-headache (PLPH) Unknown status NCT02347878 Phase 4 Aprepitant
32 Study of Standard and Individualized Treatment Model for Relapse and Refractory Lymphatic System Malignant Tumors Unknown status NCT02929615 Phase 4
33 The Efficacy and Safety of PEG-rhG-CSF in Neutropenia After Chemotherapy Unknown status NCT02905916 Phase 4 PEG-rhG-CSF
34 G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor: a Prospective, Multicentre, Randomised Controlled Trial Unknown status NCT02933333 Phase 4
35 An Open-label,Multi-center,Prospective Study of Idarubicin and Etoposide Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation for Adult Acute Lymphoblastic Leukemia Unknown status NCT01873807 Phase 4 IDA;CTX;VP-16
36 Determinants of Mercaptopurine Toxicity in Paediatric Acute Lymphoblastic Unknown status NCT03920813 Phase 4 Mercaptopurine
37 The Combination of Lower Dosage of Chemotherapy With Tyrosine Kinase Inhibitor to Treat Newly Diagnosed ph+ Acute Lymphoblastic Leukemia Patients Unknown status NCT02690922 Phase 4 Dasatinib;prednisone;dexamethasone;methotrexate
38 Plasma Kinetics of Tablet and Liquid Formulations of 6-mercaptopurine in Childhood Acute Lymphoblastic Leukemia. Unknown status NCT01906671 Phase 4 Xaluprine;Puri-Nethol
39 Philadelphia -Negative High-risk Children Acute Lymphoblastic Leukemia(ALL) Treatment:Induction Therapy:Vincristine(V),Idarubicin(I),L-asparaginase(L),Dexamethasone(D);Consolidation:V+Daunorubicin(D)+L+D, Methotrexate,Cytarabine Unknown status NCT01990807 Phase 4 Idarubicin(IDA)
40 Clinical Study of GD-2008 ALL Protocol for Childhood Acute Lymphoblastic Leukemia in Guangdong Province Unknown status NCT00846703 Phase 4 6-mercaptopurine, Methotrexate;6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone
41 PEG-asparaginase During Two Treatment Courses in the Treatment of Childhood Acute Lymphoblastic Leukemia Unknown status NCT00192673 Phase 4 PEG-asparaginase
42 Multicenter Study To Optimize Treatment in Elderly Patients (> 55 Years, No Upper Age Limit) With Acute Lymphoblastic Leukemia (GMALL Elderly 1/2003)(Amend 2) Unknown status NCT00198978 Phase 4 Cyclophosphamide;Dexamethasone / Prednisolone;Cytarabine;Idarubicin;Granulocyte-Colony-Stimulating Factor;Mercaptopurine;Methotrexate;Rituximab;HDARAC;Vincristine;Depocyte;Asparaginase
43 Medical Research Council Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia (ALL) Trial: UKALL 2003 Unknown status NCT00222612 Phase 4 Standard childhood UK ALL protocol;Intensified treatment including Capizzi maintenance
44 Ma-Spore ALL 2010 Study Unknown status NCT02894645 Phase 4 Prednisolone;Dexamethasone;L-Asparaginase;Vincristine;Methotrexate;Daunorubicin;Doxorubicin;Cyclophosphamide;Cytarabine;6-Mercaptopurine;Thioguanine;Fludarabine;Imatinib
45 Phase IV Randomized Study of Two Dose Levels of Targretin® Capsules in Subjects With Refractory Cutaneous T-Cell Lymphoma Completed NCT01007448 Phase 4 Bexarotene
46 UVADEX Sterile Solution in Conjunction With the UVAR XTS Photopheresis System as an Interventional Therapy for the Treatment Of CTCL (Mycosis Fungoides) in Patients With TMN Classification Stage 1A, 1B, 2A Completed NCT00221039 Phase 4 Methoxsalen+ECP
47 Open Label Study of ONTAK® (Denileukin Diftitox, DAB389IL-2) to Estimate Response in Cutaneous T-Cell Lymphoma (CTCL) According to CD25 Status Completed NCT00211198 Phase 4 ONTAK (denileukin difitox, DAB389IL-2)
48 Multicenter Study to Optimise Therapy of B-ALL, Burkitt's NHL and High-Grade Non-Hodgkin's Lymphoma in Adults (Amend 7) Completed NCT00199082 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone/Prednisolone;VP16;Ifosfamide;Methotrexate;G-CSF;Rituximab;Vincristine/Vindesine
49 Estimation of Carbohydrate Metabolism Disorder Frequency in Hypertriglyceridemia Induced by Bexarotene Treatment of Cutaneous T Cell Lymphoma - Pilote Study Completed NCT01569724 Phase 4
50 LINFOTARGAM: First-line Treatment With Dose-dense Chemotherapy Plus Rituximab (R-CHOP/14) and Highly Active Antiretroviral Therapy (HAART) in Patients With Diffuse Large B Cell Lymphoma (DLBCL) and Infection With the Human Immunodeficiency Virus (HIV) Completed NCT00466258 Phase 4 R-CHOP;Highly active antiretroviral therapy;Central nervous system (CNS) prophylaxis;Prophylaxis of opportunistic infections and support treatment

Search NIH Clinical Center for Lymphoma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


ASPARAGINASE
Cytarabine
Cytarabine liposome
irinotecan
Irinotecan hydrochloride
Mitoxantrone
Mitoxantrone Hydrochloride
Thiotepa

Cochrane evidence based reviews: lymphoma

Genetic Tests for Lymphoma

Genetic tests related to Lymphoma:

# Genetic test Affiliating Genes
1 Lymphoma 28

Anatomical Context for Lymphoma

Organs/tissues related to Lymphoma:

MalaCards : T Cells, Bone Marrow, Myeloid, Nk Cells, Bone, Lymph Node, B Cells

Publications for Lymphoma

Articles related to Lymphoma:

(show top 50) (show all 65364)
# Title Authors PMID Year
1
Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma. 62 5
24563539 2014
2
A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. 62 5
23023262 2012
3
Oncogenically active MYD88 mutations in human lymphoma. 62 5
21179087 2011
4
Oral and para-oral lymphomas: a 10-year multi-center retrospective study in Egypt with time series analysis and forecasting to 2030. 62 41
36457022 2022
5
CARD11 mutation and HBZ expression induce lymphoproliferative disease and adult T-cell leukemia/lymphoma. 41
36446869 2022
6
Proposed new prognostic model using the systemic immune-inflammation index for primary central nervous system lymphoma: A prospective-retrospective multicohort analysis. 41
36439151 2022
7
Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas. 53 62
20299510 2010
8
Oncogenic activation of NF-kappaB. 53 62
20516126 2010
9
Loss of p73 promotes dissemination of Myc-induced B cell lymphomas in mice. 53 62
20484818 2010
10
Common misdiagnoses in lymphomas and avoidance strategies. 53 62
20227918 2010
11
AP-1--The Jun proteins: Oncogenes or tumor suppressors in disguise? 53 62
20060892 2010
12
C/EBPβ expression in ALK-positive anaplastic large cell lymphomas is required for cell proliferation and is induced by the STAT3 signaling pathway. 53 62
20015877 2010
13
Heterogeneous expression and function of IL-21R and susceptibility to IL-21-mediated apoptosis in follicular lymphoma cells. 53 62
20193734 2010
14
Natural killer-cell receptor polymorphisms and posttransplantation non-Hodgkin lymphoma. 53 62
20207982 2010
15
Anaplastic lymphoma kinase activates the small GTPase Rap1 via the Rap1-specific GEF C3G in both neuroblastoma and PC12 cells. 53 62
20190816 2010
16
Histone acetyltransferase p300 is a coactivator for transcription factor REL and is C-terminally truncated in the human diffuse large B-cell lymphoma cell line RC-K8. 53 62
19948376 2010
17
Rac1 targeting suppresses p53 deficiency-mediated lymphomagenesis. 53 62
20179179 2010
18
DOCK2 regulates cell proliferation through Rac and ERK activation in B cell lymphoma. 53 62
20350533 2010
19
Defective ubiquitin-mediated degradation of antiapoptotic Bfl-1 predisposes to lymphoma. 53 62
20185581 2010
20
Adult T-cell leukemia/lymphoma development in HTLV-1-infected humanized SCID mice. 53 62
20124219 2010
21
microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. 53 62
20086245 2010
22
Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. 53 62
20197552 2010
23
IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice. 53 62
20190192 2010
24
Apigenin induces apoptosis via downregulation of S-phase kinase-associated protein 2-mediated induction of p27Kip1 in primary effusion lymphoma cells. 53 62
20074295 2010
25
C-C chemokine receptor 1 expression in human hematolymphoid neoplasia. 53 62
20154287 2010
26
HDM4 is overexpressed in mantle cell lymphoma and its inhibition induces p21 expression and apoptosis. 53 62
20062013 2010
27
Constituents of Carpobrotus edulis inhibit P-glycoprotein of MDR1-transfected mouse lymphoma cells. 53 62
20393003 2010
28
Characterization of D-cyclin proteins in hematolymphoid neoplasms: lack of specificity of cyclin-D2 and D3 expression in lymphoma subtypes. 53 62
20062012 2010
29
Anaplastic lymphoma kinase as a therapeutic target in anaplastic large cell lymphoma, non-small cell lung cancer and neuroblastoma. 53 62
20406193 2010
30
An uncommon case of de novo CD10+ CD5- mantle cell lymphoma mimics follicle center B cell lymphoma. 53 62
20490333 2010
31
Skp2 directs Myc-mediated suppression of p27Kip1 yet has modest effects on Myc-driven lymphomagenesis. 53 62
20197382 2010
32
VEGF-A promotes lymphoma tumour growth by activation of STAT proteins and inhibition of p27(KIP1) via paracrine mechanisms. 53 62
20064707 2010
33
BCL6, MUM1, and CD10 expression in mantle cell lymphoma. 53 62
19826251 2010
34
CD81 protein is expressed at high levels in normal germinal center B cells and in subtypes of human lymphomas. 53 62
20004001 2010
35
Determining the expression rate of the IgM and IgA in B cell lymphomas by immunohistochemistry. 53 62
20437688 2010
36
Mechanisms of chromosomal rearrangement in the human genome. 53 62
20158866 2010
37
PD-1 expression in T-cell lymphomas and reactive lymphoid entities: potential overlap in staining patterns between lymphoma and viral lymphadenitis. 53 62
20087161 2010
38
Tumor necrosis factor (TNF) and lymphotoxin-alpha (LTA) polymorphisms and risk of non-Hodgkin lymphoma in the InterLymph Consortium. 53 62
20047977 2010
39
STAT3 is a substrate of SYK tyrosine kinase in B-lineage leukemia/lymphoma cells exposed to oxidative stress. 53 62
20133729 2010
40
Lymphoid hyperplasia and lymphoma in transgenic mice expressing the small non-coding RNA, EBER1 of Epstein-Barr virus. 53 62
20161707 2010
41
Sodium valproate in combination with ganciclovir induces lysis of EBV-infected lymphoma cells without impairing EBV-specific T-cell immunity. 53 62
19196381 2010
42
Pivotal advance: Kaposi's sarcoma-associated herpesvirus (KSHV)-encoded microRNA specifically induce IL-6 and IL-10 secretion by macrophages and monocytes. 53 62
20052801 2010
43
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. 53 62
20054396 2010
44
Expression profiling of transcription factors in B- or T-acute lymphoblastic leukemia/lymphoma and burkitt lymphoma: usefulness of PAX5 immunostaining as pan-Pre-B-cell marker. 53 62
20023257 2010
45
Lymphoma cells contribute to the augmentation of plasma sL-selectins in the serum of lymphoma-bearing mice. 53 62
20001233 2010
46
TFG, a target of chromosome translocations in lymphoma and soft tissue tumors, fuses to GPR128 in healthy individuals. 53 62
19797732 2010
47
B-cell CLL/lymphoma 10 (BCL10) is required for NF-kappaB production by both canonical and noncanonical pathways and for NF-kappaB-inducing kinase (NIK) phosphorylation. 53 62
19897484 2010
48
A recombinant adenovirus type 35 fiber knob protein sensitizes lymphoma cells to rituximab therapy. 53 62
19965652 2010
49
BCL6: master regulator of the germinal center reaction and key oncogene in B cell lymphomagenesis. 53 62
20510734 2010
50
PAX5 activates the transcription of the human telomerase reverse transcriptase gene in B cells. 53 62
19806612 2010

Variations for Lymphoma

ClinVar genetic disease variations for Lymphoma:

5 (show all 15)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 PMS2 NM_000535.7(PMS2):c.736_741delinsTGTGTGTGAAG (p.Pro246_Pro247delinsCysValTer) INDEL Pathogenic
91366 rs267608150 GRCh37: 7:6037019-6037024
GRCh38: 7:5997388-5997393
2 PTPN11 NM_002834.5(PTPN11):c.188A>G (p.Tyr63Cys) SNV Pathogenic
13333 rs121918459 GRCh37: 12:112888172-112888172
GRCh38: 12:112450368-112450368
3 TP53 NM_000546.6(TP53):c.743G>A (p.Arg248Gln) SNV Likely Pathogenic
12356 rs11540652 GRCh37: 17:7577538-7577538
GRCh38: 17:7674220-7674220
4 EZH2 NM_004456.5(EZH2):c.1936T>A (p.Tyr646Asn) SNV Likely Pathogenic
376217 rs267601395 GRCh37: 7:148508728-148508728
GRCh38: 7:148811636-148811636
5 EZH2 NM_004456.5(EZH2):c.1937A>C (p.Tyr646Ser) SNV Likely Pathogenic
376218 rs267601394 GRCh37: 7:148508727-148508727
GRCh38: 7:148811635-148811635
6 EZH2 NM_004456.5(EZH2):c.1936T>C (p.Tyr646His) SNV Likely Pathogenic
76769 rs267601395 GRCh37: 7:148508728-148508728
GRCh38: 7:148811636-148811636
7 EZH2 NM_004456.5(EZH2):c.1937A>T (p.Tyr646Phe) SNV Likely Pathogenic
76768 rs267601394 GRCh37: 7:148508727-148508727
GRCh38: 7:148811635-148811635
8 EZH2 NM_004456.5(EZH2):c.2045C>G (p.Ala682Gly) SNV Likely Pathogenic
376219 rs1057519833 GRCh37: 7:148506467-148506467
GRCh38: 7:148809375-148809375
9 KMT2D NM_003482.4(KMT2D):c.10624_10625del (p.Leu3542fs) MICROSAT Likely Pathogenic
638279 rs1592123162 GRCh37: 12:49427965-49427966
GRCh38: 12:49034182-49034183
10 KMT2D NM_003482.4(KMT2D):c.11897_11911del (p.Phe3966_Gln3971delinsTer) DEL Likely Pathogenic
638280 rs1592119138 GRCh37: 12:49426577-49426591
GRCh38: 12:49032794-49032808
11 SETBP1 NM_015559.3(SETBP1):c.1703G>T (p.Ser568Ile) SNV Likely Pathogenic
638281 rs1599367044 GRCh37: 18:42531008-42531008
GRCh38: 18:44951043-44951043
12 MYD88 NM_002468.5(MYD88):c.755T>C (p.Leu252Pro) SNV Likely Pathogenic
37055 rs387907272 GRCh37: 3:38182641-38182641
GRCh38: 3:38141150-38141150
13 IDH1 NM_005896.4(IDH1):c.784G>A (p.Glu262Lys) SNV Uncertain Significance
638277 rs1574404027 GRCh37: 2:209106784-209106784
GRCh38: 2:208242060-208242060
14 NSD2 NM_001042424.3(NSD2):c.3295G>A (p.Glu1099Lys) SNV Uncertain Significance
638278 rs772470710 GRCh37: 4:1962801-1962801
GRCh38: 4:1961074-1961074
15 NBN NM_002485.5(NBN):c.93_94del (p.Ala32fs) MICROSAT Not Provided
219789 rs864622253 GRCh37: 8:90995027-90995028
GRCh38: 8:89982799-89982800

Copy number variations for Lymphoma from CNVD:

6 (show all 24)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 22797 1 168900 170100 Copy number Lymphoma
2 23565 1 171600 171900 Copy number Lymphoma
3 23675 1 172800 176700 Copy number Lymphoma
4 25326 1 187500 188100 Copy number Lymphoma
5 82146 14 105300 105900 Copy number Lymphoma
6 83536 14 21300 22200 Copy number Lymphoma
7 149232 2 88800 89400 Copy number Lymphoma
8 159014 21 39019555 39028514 Amplification KCNJ6 Lymphoma
9 159212 21 41403021 41411848 Amplification DSCAM Lymphoma
10 159621 21 43701285 43716936 Amplification ABCG1 Lymphoma
11 159656 21 43999157 44011961 Amplification SLC37A1 Lymphoma
12 159668 21 44081762 44094899 Amplification PDE9A Lymphoma
13 159699 21 44433424 44441413 Amplification PKNOX1 Lymphoma
14 159719 21 44574984 44589646 Amplification Lymphoma
15 159916 21 45919335 45928378 Amplification TSPEAR Lymphoma
16 159943 21 46246130 46270192 Amplification PTTG1IP Lymphoma
17 162160 22 21300 21600 Copy number Lymphoma
18 205715 6 13200 17100 Copy number Lymphoma
19 208659 6 1800 4200 Copy number Lymphoma
20 208796 6 19800 23100 Copy number Lymphoma
21 213994 6 5400 6300 Copy number Lymphoma
22 220996 7 141900 142200 Copy number Lymphoma
23 224818 7 38100 38700 Copy number Lymphoma
24 233910 8 128816946 128822855 Amplification MYC Lymphoma

Expression for Lymphoma

Search GEO for disease gene expression data for Lymphoma.

Pathways for Lymphoma

Pathways related to Lymphoma according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.59 BCL2 BCL3 CCND1 MYC PTPN11
2 12.36 MALT1 CXCR5 BCL6 BCL10
3
Show member pathways
12.21 PTPN11 NPM1 CCND1 BCL2
4
Show member pathways
11.83 PTPN11 MYC BCL2
5
Show member pathways
11.8 PTPN11 MYC BCL2
6 11.75 PTPN11 MYC CCND1
7 11.67 MYC CCND1 BCL2
8 11.59 MYC CCND1 BCL6 BCL2
9 11.51 MYC CCND1 BCL2
10 11.47 MYC CCND1 BCL6 BCL2
11 11.39 MALT1 BCL6 BCL10
12
Show member pathways
11.37 PTPN11 MYC MALT1 BCL2 BCL10
13 11.34 MYC CCND1 BCL2
14 11.26 MYC CCND1 BCL6 BCL2
15 11.24 PTPN11 MYC CCND1
16 10.82 MYC CCND1
17 10.77 PTPN11 CCND1
18 10.61 MYC CCND1

GO Terms for Lymphoma

Cellular components related to Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein-containing complex GO:0032991 9.58 TCL1A PTPN11 NPM1 MYC MALT1 BCL3
2 CBM complex GO:0032449 9.46 MALT1 BCL10
3 polkadots GO:0002096 9.26 MALT1 BCL10

Biological processes related to Lymphoma according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of NF-kappaB transcription factor activity GO:0051092 10.1 NPM1 MALT1 BCL10 ALK
2 positive regulation of cell population proliferation GO:0008284 10.07 TCL1A NPM1 MYC EZH2 CCND1 BCL7A
3 cellular response to DNA damage stimulus GO:0006974 10.06 BCL2 BCL3 BCL6 CCND1 MYC PMS2
4 regulation of apoptotic process GO:0042981 9.97 MALT1 BCL3 BCL2 BCL10 ALK
5 negative regulation of apoptotic process GO:0043066 9.97 BCL2 BCL3 BCL6 MALT1 MYC NPM1
6 positive regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043280 9.93 MYC MALT1 BCL10
7 T-helper 2 cell differentiation GO:0045064 9.78 BCL6 BCL3
8 response to fungus GO:0009620 9.61 MALT1 BCL10
9 regulation of T cell receptor signaling pathway GO:0050856 9.58 MALT1 BCL10
10 G1/S transition of mitotic cell cycle GO:0000082 9.56 MYC EZH2 CCND1 BCL2
11 T cell apoptotic process GO:0070231 9.1 BCL3 BCL2 BCL10

Molecular functions related to Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA-binding transcription factor binding GO:0140297 9.32 NPM1 MYC BCL6 BCL3 BCL2
2 kinase activator activity GO:0019209 9.26 MALT1 BCL10

Sources for Lymphoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....